logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9650375 B1

PDFFull Text
Date of Patent:
May. 16, 2017

Filed:

Mar. 10, 2014

Indole derivatives useful as anti-diabetic agents

Applicants:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

John J. Acton, Iii, Cranford, NJ (US);

Rajan Anand, Fanwood, NJ (US);

Ashok Arasappan, Bridgewater, NJ (US);

Qun Dang, Westfield, NJ (US);

Iyassu Sebhat, Jersey City, NJ (US);

Zhifa Pu, Shanghai, CN;

Takao Suzuki, Shanghai, CN;

Inventors:

John J. Acton, III, Cranford, NJ (US);

Rajan Anand, Fanwood, NJ (US);

Ashok Arasappan, Bridgewater, NJ (US);

Qun Dang, Westfield, NJ (US);

Iyassu Sebhat, Jersey City, NJ (US);

Zhifa Pu, Shanghai, CN;

Takao Suzuki, Shanghai, CN;

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:

Baerbel R. Brown

Catherine D. Fitch

Primary Examiner:

Niloofar Rahmani

Int. Cl.
CPC ...
C07D 209/04 (2006.01); C07D 471/04 (2006.01); A61K 31/404 (2006.01); C07D 209/12 (2006.01); C07D 209/30 (2006.01); A61K 31/366 (2006.01); A61K 31/397 (2006.01); A61K 31/437 (2006.01); A61K 31/4439 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); A61K 31/4985 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); C07D 401/04 (2006.01); C07D 401/06 (2006.01); C07D 401/10 (2006.01); C07D 403/04 (2006.01); C07D 405/04 (2006.01); C07D 405/06 (2006.01); C07D 405/10 (2006.01); C07D 413/04 (2006.01); C07D 413/10 (2006.01); C07D 493/04 (2006.01); C07D 209/18 (2006.01); C07D 519/00 (2006.01); C07D 209/08 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61K 31/366 (2013.01); A61K 31/397 (2013.01); A61K 31/404 (2013.01); A61K 31/437 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/4985 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); C07D 209/08 (2013.01); C07D 209/12 (2013.01); C07D 209/18 (2013.01); C07D 209/30 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 401/10 (2013.01); C07D 403/04 (2013.01); C07D 405/04 (2013.01); C07D 405/06 (2013.01); C07D 405/10 (2013.01); C07D 413/04 (2013.01); C07D 413/10 (2013.01); C07D 493/04 (2013.01); C07D 519/00 (2013.01);
Abstract

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

Find Patent Forward Citations

Loading…